Download presentation
Presentation is loading. Please wait.
Published byAna Belén Prado Parra Modified over 6 years ago
1
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study Naomi Mizukami, MD, Masanori Yamauchi, MD, PhD, Kazuhiko Koike, MD, PhD, Akihiko Watanabe, MD, PhD, Koji Ichihara, MD, Naoya Masumori, MD, PhD, Michiaki Yamakage, MD, PhD Journal of Pain and Symptom Management Volume 47, Issue 3, Pages (March 2014) DOI: /j.jpainsymman Copyright © 2014 U.S. Cancer Pain Relief Committee Terms and Conditions
2
Fig. 1 Distribution of FLI-E scores in the modified intention-to-treat population. FLI-E score of less than 36 indicated no effect of CINV on daily life. All patients in the OL group reported that CINV had no effect on daily activities, whereas 36% of the patients in the control group were affected. There was a significant difference between groups (P = 0.0036). FLI-E=Functional Living Index-Emesis; CINV=chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom Management , DOI: ( /j.jpainsymman ) Copyright © 2014 U.S. Cancer Pain Relief Committee Terms and Conditions
3
Fig. 2 Change in dietary intake during chemotherapy. Data are shown as a percentage of amount compared with that of Day 1. Data are shown as mean ± 95% CI. ∗P < 0.05 vs. the control group. ∗∗P < 0.01 vs. the control group. †P < 0.05 compared with Day 1 among the group. The dietary intake in the control group was significantly reduced on Days 5 and 6 compared with that on Day 1. In contrast, the OL group could maintain the amount of dietary intake during chemotherapy, and there was a significant difference on Days 2, 4, 5, and 6 between groups. Journal of Pain and Symptom Management , DOI: ( /j.jpainsymman ) Copyright © 2014 U.S. Cancer Pain Relief Committee Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.